Champignon Brands Inc.’s (CSE: SHRM) (OTC: SHRMF) (FWB: 496) New Committee Member Strengthens Compentencies

April 29, 2020 11:23:35
  • SHRM appoints former Red Bull Canada president to Special Advisory Committee
  • New member’s background in heavily regulated industries coupled with experience in CPG space provides great complement
  • Effective immediately, Champignon common shares being traded on OTCQB Venture Market

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a Canada-based company dedicated to applying novel and natural treatment protocols with an emphasis on psychedelic medicine, announced the appointment of Jim Bailey as a new member of its Special Advisory Committee. The appointment of Bailey, a former president of Red Bull Canada, is designed to strengthen SHRM’s pharmaceutical, nutraceutical and CPG marketing/distribution competencies (

“I am very excited to be part of a company that is leading the way in finding alternative solutions to traditional pharmaceuticals with science-based research and functional products,” Bailey noted in a news release. “My background in heavily regulated industries coupled with my experience in the CPG space provides a great complement to an already talented and experienced advisory board.”

In his position at Red Bull Canada, Bailey played a key role in introducing the Red Bull brand in Canada and growing the business to $150 million in annual revenue with more than 300 employees. In addition to his experience at Red Bull, Bailey served as the global chief marketing office for Merrell Outdoors, overseeing both product and consumer marketing; during his tenure, Merrell Outdoors reported annual revenues of up to $600 million.

In his new position on Champignon’s Special Advisory Committee, Bailey will “champion the marketing, distribution and commercialization of the company’s Novoformulations-branded novel delivery systems for the pharmaceutical, nutraceutical and psychedelic medicine industries,” the company announced.

A wholly owned subsidiary of Champignon, Novoformulations is focused on working with ketamine, anaesthetics and adaptogenics, along with other pharmaceuticals and natural molecules at a purpose-built good manufacturing practice (GMP) and pharmaceutical (DIN) licensed facility located in Quebec. As part of these efforts, Novoformulations is formulating, developing and working to commercialize bioavailable transdermal, intranasal and sublingual delivery platforms.

In addition, Champignon announced that, effective immediately, its common shares are being traded on the OTCQB Venture Market, a U.S. trading platform operated by the OTC Markets Group; the shares will be traded under the ticker ‘SHRMF’ ( Champignon’s common shares will continue to trade on the Canadian Securities Exchange under the ticker symbol ‘SHRM’, as well as on the quotation board of the Frankfurt Stock Exchange under the ticker symbol ‘496’.

The OTCQB is the foremost exchange for entrepreneurial and development-stage U.S. and international companies focused on providing superior experience for U.S. investors. To trade on the market, companies must be current in their financial reportings, pass a minimum-bid price test, and undergo an annual company verification and management certification process. Companies that are approved to trade on the OTCQB exchange have met quality standards that provide a strong baseline of transparency and are committed to improving the information and trading experience for investors.

Champignon seeks opportunities to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health-care and pharmaceutical products. The company’s flagship e-commerce store,, takes advantage of the burgeoning craft mushroom industry with a selection of mushroom-infused teas and accessories; SHRM is also expanding its preclinical trial pipeline and branching out into alternative medicine and pharmaceuticals.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.